

Sergey Moiseev

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5856854/publications.pdf>

Version: 2024-02-01

152
papers

2,660
citations

361045

20
h-index

205818

48
g-index

164
all docs

164
docs citations

164
times ranked

3950
citing authors

#	ARTICLE	IF	CITATIONS
1	Neither earlier nor late tocilizumab improved outcomes in the intensive care unit patients with COVID-19 in a retrospective cohort study. <i>Annals of the Rheumatic Diseases</i> , 2023, 82, e3-e3.	0.5	12
2	Mepolizumab for Eosinophilic Granulomatosis With Polyangiitis: A European Multicenter Observational Study. <i>Arthritis and Rheumatology</i> , 2022, 74, 295-306.	2.9	78
3	Assessment of hemostasis disorders using thromboelastography in patients with chronic glomerulonephritis and nephrotic syndrome. <i>Profilakticheskaya Meditsina</i> , 2022, 25, 84.	0.2	0
4	Clinical variants of lesions of the nervous system in ANCA-associated vasculitis. <i>Vrach</i> , 2022, 33, 5-9.	0.0	1
5	Leading Factors of Progression in Patients with Cardiac Amyloidosis. <i>Rational Pharmacotherapy in Cardiology</i> , 2022, 18, 143-152.	0.3	1
6	Organizing pneumonia as a pulmonary manifestation of post-COVID syndrome: features of diagnosis and treatment. <i>Terapevticheskii Arkhiv</i> , 2022, 94, 497-502.	0.2	1
7	Risk factors for invasive and non-invasive ventilatory support and mortality in hospitalized patients with COVID-19. <i>Medicina Intensiva (English Edition)</i> , 2022, 46, 355-356.	0.1	0
8	Classification of systemic vasculitis: evolution from eponyms to modern criteria. <i>Terapevticheskii Arkhiv</i> , 2022, 94, 704-708.	0.2	2
9	Gut microbiome in rheumatic diseases. <i>Annals of the Rheumatic Diseases</i> , 2021, 80, e176-e176.	0.5	2
10	Is there a future for hydroxychloroquine/chloroquine in prevention of SARS-CoV-2 infection (COVID-19)?. <i>Annals of the Rheumatic Diseases</i> , 2021, 80, e19-e19.	0.5	9
11	Rheumatic diseases in intensive care unit patients with COVID-19. <i>Annals of the Rheumatic Diseases</i> , 2021, 80, e16-e16.	0.5	22
12	Sex differences in mortality in the intensive care unit patients with severe COVID-19. <i>Journal of Infection</i> , 2021, 82, 282-327.	1.7	7
13	Outcomes of intensive care unit patients with COVID-19: a nationwide analysis in Russia. <i>Anaesthesia</i> , 2021, 76, 11-12.	1.8	10
14	Association of venous thromboembolic events with skin, pulmonary and kidney involvement in ANCA-associated vasculitis: a multinational study. <i>Rheumatology</i> , 2021, 60, 4654-4661.	0.9	20
15	Sarcoidosis and primary biliary cholangitis in a patient with cholestasis. <i>Terapevticheskii Arkhiv</i> , 2021, 93, 193-198.	0.2	0
16	Methotrexate-induced lung damage in a patient with rheumatoid arthritis. <i>Terapevticheskii Arkhiv</i> , 2021, 93, 295-299.	0.2	0
17	OP0008...A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED PHASE III TRIAL OF IVIG 10% IN PATIENTS WITH DERMATOMYOSITIS. THE PRODERM STUDY: RESULTS ON EFFICACY AND SAFETY. <i>Annals of the Rheumatic Diseases</i> , 2021, 80, 4.1-5.	0.5	4
18	Acute kidney injury and mortality in coronavirus disease 2019: results from a cohort study of 1,280 patients. <i>Kidney Research and Clinical Practice</i> , 2021, 40, 241-249.	0.9	10

#	ARTICLE	IF	CITATIONS
19	Role of the intestinal MALT in pathogenesis of the IgA-nephropathy. <i>Terapevticheskii Arkhiv</i> , 2021, 93, 724-728.	0.2	0
20	The state of cytokine regulation and endothelial dysfunction in the combined course of vibration disease and arterial hypertension. <i>Terapevticheskii Arkhiv</i> , 2021, 93, 693-698.	0.2	3
21	Coronavirus Disease 2019 (COVID-19) and Immune-mediated Rheumatic Diseases. Recommendations of the Association of Rheumatologists of Russia. <i>Nauchno-Prakticheskaya Revmatologiya</i> , 2021, 59, 239-254.	0.2	40
22	Delisting and clinical outcomes of liver transplant candidates after hepatitis C virus eradication: A long-term single-center experience. <i>Clinics and Research in Hepatology and Gastroenterology</i> , 2021, 45, 101714.	0.7	5
23	Upper respiratory tract manifestations in patients with ANCA-associated vasculitides and their association with the presence and type of ANCA. <i>Nauchno-Prakticheskaya Revmatologiya</i> , 2021, 59, 555-562.	0.2	0
24	Urinary Protein and Peptide Markers in Chronic Kidney Disease. <i>International Journal of Molecular Sciences</i> , 2021, 22, 12123.	1.8	14
25	Influence of Genetic Factors on Immunopathogenesis and Clinical Phenotypes of ANCA-associated Vasculitis. <i>Vestnik Rossiiskoi Akademii Meditsinskikh Nauk</i> , 2021, 76, 642-651.	0.2	0
26	Prevention of infections in patients with antineutrophil cytoplasm antibody-associated vasculitis: potential role of hydroxychloroquine. <i>Annals of the Rheumatic Diseases</i> , 2020, 79, e19-e19.	0.5	3
27	Changing landscape of immunosuppression in ANCA-associated vasculitis. <i>Annals of the Rheumatic Diseases</i> , 2020, 79, e59-e59.	0.5	2
28	What rheumatologist should know about Fabry disease. <i>Annals of the Rheumatic Diseases</i> , 2020, 79, e71-e71.	0.5	9
29	Assessing Cardiovascular Risk in Patients With Antineutrophil Cytoplasmic Antibody-associated Vasculitis: Comment on the Article by Wallace et al. <i>Arthritis and Rheumatology</i> , 2020, 72, 200-201.	2.9	3
30	The road to biosimilars in rare diseases – ongoing lessons from Gaucher disease. <i>American Journal of Hematology</i> , 2020, 95, 233-237.	2.0	9
31	Rituximab in adult minimal change disease and focal segmental glomerulosclerosis - What is known and what is still unknown?. <i>Autoimmunity Reviews</i> , 2020, 19, 102671.	2.5	37
32	2020 international consensus on ANCA testing beyond systemic vasculitis. <i>Autoimmunity Reviews</i> , 2020, 19, 102618.	2.5	79
33	Letter to the Editor: Virtual Care for Critically Ill Patients with COVID-19. <i>Telemedicine Journal and E-Health</i> , 2020, 26, 1326-1327.	1.6	2
34	Antineutrophil cytoplasmic autoantibody (ANCA) positive immunoglobulin A (IgA) nephropathy: Case reports and review of literature. <i>Egyptian Rheumatologist</i> , 2020, 42, 251-254.	0.5	6
35	The alternative complement pathway in ANCA-associated vasculitis: further evidence and a meta-analysis. <i>Clinical and Experimental Immunology</i> , 2020, 202, 394-402.	1.1	34
36	Lingual and digital necrosis in microscopic polyangiitis. <i>Rheumatology</i> , 2020, 59, 3582-3583.	0.9	1

#	ARTICLE	IF	CITATIONS
37	P0081IMPACT OF RENAL FAILURE ON OVERALL SURVIVAL OF PATIENTS WITH FABRY DISEASE. Nephrology Dialysis Transplantation, 2020, 35, .	0.4	0
38	P0450END-STAGE RENAL DISEASE PREDICTION IN ANCA-ASSOCIATED GLOMERULONEPHRITIS AT BASELINE: UTILITY OF DIFFERENT APPROACHES IN CLINICAL PRACTICE. Nephrology Dialysis Transplantation, 2020, 35, .	0.4	0
39	Predictive Value of Cardiac MRI in Patients with Fabry Disease. Radiology, 2020, 296, E123-E123.	3.6	5
40	Is there enough evidence to discontinue the renin-angiotensin system inhibitors in patients with COVID-19?. Medical Hypotheses, 2020, 143, 109888.	0.8	0
41	Hepatocellular carcinoma surveillance after hepatitis C virus eradication: Is liver stiffness measurement more useful than laboratory fibrosis markers?. Journal of Hepatology, 2020, 73, 469-470.	1.8	4
42	Low prevalence of bronchial asthma and chronic obstructive lung disease among intensive care unit patients with COVID-19. Allergy: European Journal of Allergy and Clinical Immunology, 2020, 75, 2703-2704.	2.7	53
43	Is There a Role for LAMP-2 Autoantibodies in Patients with Antineutrophil Cytoplasmic Antibody-associated Vasculitis?. Journal of Rheumatology, 2020, 47, 636-638.	1.0	0
44	Elevated Fibroblast Growth Factor 23 and Decreased Klotho Levels Are Associated With Diastolic Dysfunction in CKD G4-5D Patients. Kidney International Reports, 2020, 5, 1118.	0.4	3
45	International Consensus on Antineutrophil Cytoplasm Antibodies Testing in Eosinophilic Granulomatosis with Polyangiitis. American Journal of Respiratory and Critical Care Medicine, 2020, 202, 1360-1372.	2.5	36
46	Cancer in intensive care unit patients with COVID-19. Journal of Infection, 2020, 81, e124-e125.	1.7	9
47	Myocardial Infarction Due to Takayasu Arteritis in Adults: Look Out for Multivascular Involvement and Signs of Systemic Inflammation. Canadian Journal of Cardiology, 2020, 36, 969.e11.	0.8	3
48	Heat shock protein 90 and NFκB levels in serum and urine in patients with chronic glomerulonephritis. Cell Stress and Chaperones, 2020, 25, 495-501.	1.2	11
49	SAT0268...COMPLEMENT ACTIVATION VIA ALTERNATIVE PATHWAY IN ANCA-ASSOCIATED VASCULITIS. Annals of the Rheumatic Diseases, 2020, 79, 1077-1078.	0.5	2
50	AB0497...RENAL INVOLVEMENT IN ANCA-ASSOCIATED VASCULITIS: DO THE PRESENCE OF ANCA AND THEIR TYPE MATTER?. Annals of the Rheumatic Diseases, 2020, 79, 1546.2-1547.	0.5	0
51	An association between sarcoidosis and serum immunoglobulin levels. , 2020, , .		0
52	Clinical impact of plasma haemostasis disorders and their correction in chronic glomerulonephritis with nephrotic syndrome. Gematologiya I Transfuziologiya, 2020, 65, 473-482.	0.1	1
53	Immunological features and prognosis in modern forms of occupational lung diseases. Meditsina Truda I Promyshlennaia Ekologiya, 2020, , 81-88.	0.1	6
54	Liver fibrosis assessment by transient elastography in patients with liver cirrhosis after hepatitis C virus eradication. SeĀenovskij Vestnik, 2020, 11, 26-37.	0.3	0

#	ARTICLE	IF	CITATIONS
55	Lung involvement in primary biliary cholangitis (PBC). , 2020, , .		0
56	Interstitial pneumonia with autoimmune features (IPAF): the relationship between radiological and clinical features. , 2020, , .		0
57	Rituximab in ANCA-associated vasculitis: fewer infusions or ultra low-dose maintenance therapy?. Annals of the Rheumatic Diseases, 2019, 78, e99-e99.	0.5	2
58	Role of tubulointerstitial injury in ANCA-associated vasculitis is underestimated. Annals of the Rheumatic Diseases, 2019, 78, e111-e111.	0.5	5
59	Vasodilators and low-dose acetylsalicylic acid are associated with a lower incidence of distinct primary myocardial disease manifestations in systemic sclerosis: results of the DeSSciper inception cohort study. Annals of the Rheumatic Diseases, 2019, 78, 1576-1582.	0.5	31
60	The critical role of chronic kidney disease in the progression of AL-amyloid cardiopathy. Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis, 2019, 26, 109-110.	1.4	0
61	SP009CHRONIC KIDNEY DISEASE AS A PREDICTOR OF CLINICAL OUTCOMES IN PATIENTS WITH FABRY DISEASE. Nephrology Dialysis Transplantation, 2019, 34, .	0.4	0
62	SP026MORTALITY IN PATIENTS WITH FABRY DISEASE AND END-STAGE RENAL FAILURE. Nephrology Dialysis Transplantation, 2019, 34, .	0.4	0
63	D-penicillamine-induced autoimmune disorders. Digestive and Liver Disease, 2019, 51, 1741-1742.	0.4	5
64	328.â€fATYPICAL HEMOLYTIC UREMIC SYNDROME ASSOCIATED WITH DIACYLGLYCEROL KINASE-E MUTATION IN A PATIENT WITH MICROSCOPIC POLYANGIITIS: A POSSIBLE RELATIONSHIP VIA COMPLEMENT ACTIVATION?. Rheumatology, 2019, 58, .	0.9	1
65	Strategies of Screening for Fabry Disease in Patients with Unexplained Left Ventricular Hypertrophy. Mayo Clinic Proceedings, 2019, 94, 1644-1646.	1.4	2
66	Glomerular Hyperfiltration or Microalbuminuria as an Early Marker of Fabry Nephropathy. Nephron, 2019, 143, 133-134.	0.9	1
67	SAT-252-Long-term effect of direct-acting antivirals therapy in patients with hepatitis C-related decompensated cirrhosis: Russian single academic center experience. Journal of Hepatology, 2019, 70, e744.	1.8	0
68	Efficacy and Safety of Belimumab and Azathioprine for Maintenance of Remission in Antineutrophil Cytoplasmic Antibodyâ€Associated Vasculitis: A Randomized Controlled Study. Arthritis and Rheumatology, 2019, 71, 952-963.	2.9	82
69	The Prevalence and Clinical Features of Fabry Disease in Hemodialysis Patients: Russian Nationwide Fabry Dialysis Screening Program. Nephron, 2019, 141, 249-255.	0.9	19
70	Mepolizumab in patients with eosinophilic granulomatosis with polyangiitis. Journal of Allergy and Clinical Immunology, 2019, 144, 621.	1.5	4
71	104.â€fEOSINOPHILIC GRANULOMATOSIS WITH POLYANGIITIS REVISITED: UTILITY OF CRITERIA FOR GENUINE VASCULITIS IN CLINICAL PRACTICE. Rheumatology, 2019, 58, .	0.9	0
72	034.â€fDOES THE PRESENCE OF ANTI-NEUTROPHIL CYTOPLASMIC ANTIBODIES CHANGE THE CLINICAL FEATURES AND PROGNOSIS IN GRANULOMATOSIS WITH POLYANGIITIS?. Rheumatology, 2019, 58, .	0.9	0

#	ARTICLE	IF	CITATIONS
73	Gastroesophageal Reflux and Serum Biomarkers in Systemic Sclerosis-associated Interstitial Lung Disease: Comment on the Article by Elhai et al. Arthritis and Rheumatology, 2019, 71, 1203-1204.	2.9	0
74	DIFFERENCES IN PATIENT THERAPY WITH HYPEREOSINOPHILIC ASTHMA WITH SYSTEMIC MANIFESTATIONS AND EOSINOPHILIC GRANULOMATOSIS WITH POLYANGIITIS. Rheumatology, 2019, 58, .	0.9	0
75	Lyso-Gb3 is as a primary biomarker for Fabry disease screening among high-risk contingents. Molecular Genetics and Metabolism, 2019, 126, S130.	0.5	0
76	Pelvic Electric Potential as a Marker of Autonomic Dysfunctions and Risk Factor of Neurogenic Arrhythmias in Humans. Bulletin of Experimental Biology and Medicine, 2019, 166, 404-408.	0.3	0
77	SAT0229...INTESTINAL PERMEABILITY IN IGA-VASCULITIS IN ADULTS. , 2019, , .		0
78	AB0631...INTERSTITIAL LUNG DISEASE " A RARE MANIFESTATION OF MICROSCOPIC POLYANGIITIS. , 2019, , .		0
79	4310Left ventricular myocardial mass index is a predictor of clinical outcomes in patients with Fabry disease. European Heart Journal, 2019, 40, .	1.0	0
80	Childhood-versus Adult-onset Takayasu Arteritis: Are They Really Different? Comment on the Article by Aeschlimann et al. Arthritis and Rheumatology, 2019, 71, 835-836.	2.9	0
81	Diagnostic Pitfalls and Treatment Challenges in Interstitial Pneumonia With Autoimmune Features: Comment on the Article by Wilfong et al. Arthritis and Rheumatology, 2019, 71, 651-652.	2.9	8
82	The role of temporal artery biopsy in patients with giant-cell arteritis is debated. Annals of the Rheumatic Diseases, 2019, 78, e31-e31.	0.5	10
83	Tofacitinib in steroid-dependent relapsing polychondritis. Annals of the Rheumatic Diseases, 2019, 78, e72-e72.	0.5	11
84	Autoimmune liver disease (primary biliary cholangitis/autoimmune hepatitis-overlap) associated with sarcoidosis (clinical cases and literature review). Terapevticheskii Arkhiv, 2019, 91, 89-94.	0.2	4
85	Risk factors of unfavorable prognosis of chronic hepatitis C. Terapevticheskii Arkhiv, 2019, 91, 59-66.	0.2	7
86	Efficacy and safety of long-term therapy with nucleos(t)ide analogues in chronic hepatitis B. Terapevticheskii Arkhiv, 2019, 91, 40-47.	0.2	2
87	The role of obesity in patients with sarcoidosis. , 2019, , .		0
88	Lung involvement in autoimmune liver diseases. , 2019, , .		0
89	Efficacy and safety of tregalizumab in patients with rheumatoid arthritis and an inadequate response to methotrexate: results of a phase IIb, randomised, placebo-controlled trial. Annals of the Rheumatic Diseases, 2018, 77, 495-499.	0.5	10
90	ANCA-associated vasculitis: mission incomplete. Annals of the Rheumatic Diseases, 2018, 77, e8-e8.	0.5	3

#	ARTICLE	IF	CITATIONS
91	Does the Revised Definition of Eosinophilic Granulomatosis With Polyangiitis (Churgâ€Strauss) Indicate the Need for a New Treatment? Comment on the Article by PuÃ©chal et al. Arthritis and Rheumatology, 2018, 70, 149-151.	2.9	0
92	2356Cardiac magnetic resonance imaging in Fabry cardiomyopathy. European Heart Journal, 2018, 39, .	1.0	1
93	SP006CLINICAL MANIFESTATIONS AND PREVALENCE OF FABRY DISEASE IN HEMODIALYSIS PATIENTS. Nephrology Dialysis Transplantation, 2018, 33, i348-i348.	0.4	0
94	Low aquaporin-2 excretion in the nephrotic syndrome: an escape from the vasopressin regulating effect. International Journal of Nephrology and Renovascular Disease, 2018, Volume 11, 271-277.	0.8	2
95	Sofosbuvir-based salvage therapy for HCV infection in cirrhotic patients with DAA failure and multidrug resistance. Antiviral Therapy, 2018, 23, 705-708.	0.6	6
96	Albiglutide and cardiovascular outcomes in patients with type 2 diabetes and cardiovascular disease (Harmony Outcomes): a double-blind, randomised placebo-controlled trial. Lancet, The, 2018, 392, 1519-1529.	6.3	1,179
97	Effect of essential amino acid D°etoanalogues and protein restriction diet on morphogenetic proteins (FGF-23 and Dšlotho) in 3bâ€4 stages chronic D°idney disease patients: a randomized pilot study. Clinical and Experimental Nephrology, 2018, 22, 1351-1359.	0.7	26
98	Heat shock protein 70 and anti-heat shock protein 70 antibodies in patients with chronic glomerulonephritis. Cell Stress and Chaperones, 2018, 23, 1229-1235.	1.2	8
99	Certolizumab pegol in the treatment of Takayasu arteritis. Rheumatology, 2018, 57, 2101-2105.	0.9	21
100	Usual interstitial pneumonia: A distinct group within interstitial pneumonia with autoimmune features?. Respiriology, 2018, 23, 958-958.	1.3	0
101	SAT0627â€...Fabry disease: diagnostic errors in rheumatology practice. , 2018, , .		1
102	SAT0524â€...The role of polymorphisms of hemostasis genes in venous thromboembolic events in anca-associated vasculitides. , 2018, , .		1
103	The first russian expert consensus on the quantitative evaluation of the treatment adherence: pivotal issues, algorithms and recommendations. Medical News of North Caucasus, 2018, 13, .	0.0	22
104	Cornea verticillata in Fabry disease. Terapevticheskii Arkhiv, 2018, 90, 17-22.	0.2	7
105	From SchÃ¶nleinâ€Henoch purpura to IgA-vasculitis: pathogenetic aspects of the disease. Terapevticheskii Arkhiv, 2018, 90, 109-114.	0.2	2
106	Relationship between serologic profile (ANCA type) and clinical features of renal involvement in ANCA-associated vasculitides. Terapevticheskii Arkhiv, 2018, 90, 15-21.	0.2	5
107	The modern therapy of systemic vasculitides: perspectives and challenges. Terapevticheskii Arkhiv, 2018, 90, 76-85.	0.2	2
108	Modern approaches to the diagnosis and treatment of microscopic polyangiitis.. Klinicheskaia Meditsina, 2018, 96, 66-72.	0.2	1

#	ARTICLE	IF	CITATIONS
109	FRI0478â€¦Occurrence of genuine vasculitis in patients with eosinophilic granulomatosis with polyangiitis. , 2018, , .		0
110	Clinical features of kidney involvement in microscopic microscopic polyangiitis. <i>Terapevticheskii Arkhiv</i> , 2018, 90, 55-58.	0.2	1
111	SAT0529â€¦Short-term efficacy and safety of biosimilar rituximab in patients with systemic vasculitides. , 2018, , .		0
112	Arterial hypertension at the workplace: risk factors and the population value. <i>Terapevticheskii Arkhiv</i> , 2018, 90, 138-143.	0.2	4
113	The role of genetic thrombophilia for venous thromboembolic events in anca-associated vasculitides.. <i>Klinicheskaiia Meditsina</i> , 2018, 96, 620-625.	0.2	0
114	End-stage renal disease in ANCA-associated vasculitis. <i>Nephrology Dialysis Transplantation</i> , 2017, 32, gfw046.	0.4	51
115	Testing for antineutrophil cytoplasmic antibodies (ANCA) in patients with systemic vasculitides and other diseases. <i>Annals of the Rheumatic Diseases</i> , 2017, 76, e23-e23.	0.5	7
116	Giant cell arteritis, infections and biologics. <i>Annals of the Rheumatic Diseases</i> , 2017, 76, e29-e29.	0.5	4
117	HCV-associated cryoglobulinemia vasculitis: are its days numbered?. <i>Annals of the Rheumatic Diseases</i> , 2017, 76, e5.	0.5	3
118	Personalized Biologic Therapy for Large Vessel Vasculitis: Comment on the Articles by Langford et al. <i>Arthritis and Rheumatology</i> , 2017, 69, 1504-1505.	2.9	0
119	Biologic Therapy for Eosinophilic Granulomatosis With Polyangiitis (Churgâ€¦Strauss): Comment on the Article by Jachiet et al. <i>Arthritis and Rheumatology</i> , 2017, 69, 870-871.	2.9	0
120	Revised 2017 international consensus on testing of ANCA in granulomatosis with polyangiitis and microscopic polyangiitis. <i>Nature Reviews Rheumatology</i> , 2017, 13, 683-692.	3.5	302
121	Duration of maintenance therapy for ANCA-associated vasculitis: more questions than answers. <i>Annals of the Rheumatic Diseases</i> , 2017, 77, annrheumdis-2017-211972.	0.5	3
122	Rituximab for Antineutrophil Cytoplasmic Antibodyâ€¦Associated Vasculitisâ€¦Not Everything in the Garden Is Rosy: Comment on the Article by Cortazar et al. <i>Arthritis and Rheumatology</i> , 2017, 69, 2094-2095.	2.9	0
123	THU0338â€¦Clinical presentation and outcomes of eosinophilic granulomatosis with polyangiitis: anca-negative versus anca-positive. , 2017, , .		0
124	FRI0346â€¦Renal involvement in granulomatosis with polyangiitis. , 2017, , .		0
125	OP0057â€¦Urinary and Serum KIM-1, MCP-1 and Type IV Collagen Levels in The Assessment of ANCA-Associated Nephritis Activity:. <i>Annals of the Rheumatic Diseases</i> , 2016, 75, 76.1-76.	0.5	1
126	AB0564â€¦Short-Term Results of The New Anti-TNF Treatment with Certolizumab Pegol in Refractory Takayasu's Arteritis. <i>Annals of the Rheumatic Diseases</i> , 2016, 75, 1097.2-1097.	0.5	0

#	ARTICLE	IF	CITATIONS
127	Tocilizumab for polymyalgia rheumatica: a first or second line?. <i>Annals of the Rheumatic Diseases</i> , 2016, 75, e47-e47.	0.5	3
128	Biological agents for giant cell arteritis: treat to target. <i>Annals of the Rheumatic Diseases</i> , 2016, 75, e58-e58.	0.5	5
129	Letter: cure of chronic hepatitis B and D after 12 years of treatment with low-dose standard interferon alfa-2b. <i>Alimentary Pharmacology and Therapeutics</i> , 2016, 44, 649-650.	1.9	1
130	Cryofibrinogenaemia—a neglected disease. <i>Rheumatology</i> , 2016, 56, kew379.	0.9	8
131	Eotaxin-3 as a Biomarker of Activity in Established Eosinophilic Granulomatosis with Polyangiitis. <i>Journal of Rheumatology</i> , 2016, 43, 2082-2083.	1.0	2
132	SAT0348—Asymptomatic Deep Vein Thrombosis in Anca-Associated Vasculitides. <i>Annals of the Rheumatic Diseases</i> , 2016, 75, 793.1-793.	0.5	0
133	SAT0361—Kidney Involvement in Microscopic Polyangiitis—Russian Experience. <i>Annals of the Rheumatic Diseases</i> , 2016, 75, 797.3-797.	0.5	0
134	Le rituximab comme traitement d'induction dans la granulomatose éosinophilique avec polyangite (syndrome de Churg et Strauss): À propos de 6 cas. <i>Revue Du Rhumatisme (Edition Francaise)</i> , 2016, 83, 62-65.	0.0	0
135	Bortezomib in refractory ANCA-associated vasculitis: a new option?. <i>Annals of the Rheumatic Diseases</i> , 2016, 75, e9-e9.	0.5	25
136	Rituximab as induction therapy in relapsing eosinophilic granulomatosis with polyangiitis: A report of 6 cases. <i>Joint Bone Spine</i> , 2016, 83, 81-84.	0.8	19
137	FRI0273—The Diagnostic Value of Ultrasound Examination of Ocular and Orbital Blood Flow in Patients with Giant-Cell Arteritis. <i>Annals of the Rheumatic Diseases</i> , 2015, 74, 523.2-523.	0.5	1
138	THU0293—Safety and Efficacy of Short-Term Treatment with Tocilizumab in Patients with Refractory Takayasu Arteritis. <i>Annals of the Rheumatic Diseases</i> , 2015, 74, 302.1-302.	0.5	4
139	SAT0546—Clinical Manifestations and Features of Cryofibrinogenemia: Russian Experience. <i>Annals of the Rheumatic Diseases</i> , 2015, 74, 857.4-858.	0.5	1
140	AB0069—Cytokines Genes Expression in Peripheral Blood in Patients with Localized and Generalized Forms of Granulomatosis with Polyangiitis: Table 1.. <i>Annals of the Rheumatic Diseases</i> , 2015, 74, 913.3-914.	0.5	0
141	Venous thromboembolic events in systemic vasculitis: Table 1. <i>Annals of the Rheumatic Diseases</i> , 2015, 74, e27-e27.	0.5	31
142	Changing patterns of clinical severity and risk of mortality in granulomatosis with polyangiitis over four decades: the Russian experience. <i>Rheumatology International</i> , 2015, 35, 891-898.	1.5	11
143	Predictors of AA amyloidosis in familial Mediterranean fever. <i>Rheumatology International</i> , 2015, 35, 1257-1261.	1.5	29
144	Classification, diagnosis and treatment of ANCA-associated vasculitis. <i>World Journal of Rheumatology</i> , 2015, 5, 36.	0.5	7

#	ARTICLE	IF	CITATIONS
145	Five Factor Score in patients with eosinophilic granulomatosis with polyangiitis (Churgâ€“Strauss); Tj ETQq1 1 0.784314 rgBj /Overl	0.5	6
146	Positron emission tomography in giant cell arteritis: a new diagnostic tool?. Annals of the Rheumatic Diseases, 2014, 73, e70-e70.	0.5	6
147	HCV-associated cryoglobulinaemic vasculitis: triple/dual antiviral treatment and/or rituximab?. Annals of the Rheumatic Diseases, 2014, 73, e58-e58.	0.5	7
148	Tumor necrosis factor alpha inhibitors in patients with Takayasu's arteritis refractory to standard immunosuppressive treatment: cases series and review of the literature. Clinical Rheumatology, 2013, 32, 1827-1832.	1.0	31
149	Successful pregnancy in patients with granulomatosis with polyangiitis (Wegener's) after rituximab treatment. Presse Medicale, 2013, 42, 709.	0.8	0
150	SAT0179â€“Efficacy and Safety of Rituximab in Patients with SLE And Systemic Vasculitides. Annals of the Rheumatic Diseases, 2013, 72, A642.1-A642.	0.5	1
151	Polymorphic minisatellite ecNOS4a/4b of the endothelial NO synthase gene and cardiovascular disorders. Molecular Biology, 2000, 34, 744-746.	0.4	0
152	NON-INVASIVE DIAGNOSIS OF CARDIAC SARCOIDOSIS. Lancet, The, 1987, 330, 739-740.	6.3	6